Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIR-Spheres + CIS-GEM vs CIS-GEM in Intrahepatic Cholangiocarcinoma
NCT02807181Phase 3Terminated
- Sponsor
- Sirtex
- Start
- Feb 2017
- Primary completion
- Apr 2021
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Sirtex. Primary endpoint: Survival at 18 Months. Started Feb 2017; status: terminated.
Beyond the preview
Go deeper on NCT02807181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807181.